Recently, the interleukin-18 cytokine gene (IL18) was reported to be associated with type 1 diabetes. In the present report, we calculated that the reported genotypes of the two 5 region/promoter single nucleotide polymorphisms (SNPs), ؊607 (C3 A) (rs1946518) and ؊137 (G3 C) (rs187238), were not in Hardy-Weinberg equilibrium (HWE). We therefore investigated the association of the ؊607 and ؊137 SNPs in a U.K. type 1 diabetic Caucasian case-control collection (1,560 case and 1,715 control subjects tested at ؊607 and 4,323 case and 4,610 control subjects tested at ؊137) as well as a type 1 diabetic Caucasian collection comprised of families of European ancestry (1,347 families tested at ؊137 and 1,356 families tested at ؊607). No evidence for association with type 1 diabetes was found, including for the ؊607 A/A and C/A genotypes. To evaluate whether common variation elsewhere in the gene was associated with disease susceptibility, we analyzed eight IL18 tag SNPs in a type 1 diabetic case-control collection (1,561 case and 1,721 control subjects). No evidence for association was obtained (P ‫؍‬ 0.11). We conclude that common allelic variation in IL18 is unlikely to contribute substantially to type 1 diabetes susceptibility in the populations tested and recommend routine application of tests for HWE in population-based studies for genetic association. Diabetes 55:559 -562, 2006
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nterleukin (IL)-18 is a strong candidate for association studies with type 1 diabetes, as prior biological information exists and a central role for this inflammatory cytokine in autoimmunity has been shown (1) (2) (3) (4) (5) (6) . Two single nucleotide polymorphisms (SNPs) in the gene promoter located at positions Ϫ607 (C3 A) and Ϫ137 (G3 C) are present in European American subjects at minor allele frequencies (MAFs) of 0.46 and 0.30, respectively (estimates obtained from the Innate Immunity Programs for Genomic Applications [IIPGA] database located at http://www.innateimmunity.net). These promoter SNPs have been associated with decreased IL18 expression (7) . Allele C at Ϫ137 (G3 C) has been shown experimentally to disrupt a confirmed H4TF-1-binding site, while nucleotide substitution at Ϫ607 (C3 A) may disrupt a potential cAMP-responsive element-binding site (7) . In an IL18 promoter transcription activity assay, Giedraitis et al. (7) demonstrated low promoter activity following stimulation for both the A and C alleles at positions Ϫ607 (C3 A) and Ϫ137 (G3 C) when present on the same haplotype. These results are suggestive of functionality, rendering these promoter SNPs attractive candidates in tests for genetic association with immune-mediated diseases.
These promoter SNPs have also been implicated as susceptibility loci for various diseases, including type 1 diabetes (8, 9) , rheumatoid arthritis (10,11), sarcoidosis (12) , atopic eczema (13), adult-onset Still's disease (14) , and seasonal allergic rhinitis (15) . At Ϫ137 (G3 C), for example, the C allele showed evidence for a positive association with atopic eczema, seasonal allergic rhinitis, and type 1 diabetes (8, 13, 15) . At Ϫ607 (C3 A), the A allele and the A/A genotype were reported to be negatively associated with sarcoidosis in a Japanese sample and with rheumatoid arthritis in a Chinese sample (10,12). In type 1 diabetes, Kretowski et al. (8) genotyped 201 case and 194 unrelated control subjects from Poland and reported that the C allele at Ϫ137 (G3 C) was associated with type 1 diabetes (odds ratio [OR] 1.6; P ϭ 0.002). Kretowski et al. also obtained evidence for a genotypic effect at Ϫ137 (P ϭ 0.0015), noting an increase, in case subjects, in the proportion of G/C (62.2% case and 48.5% control) and C/C (6.5% case and 3.0% control) genotypes. In addition, they reported that disease risk conferred by a given genotype at Ϫ137 (G3 C) varied according to the genotype at Ϫ607 (C3 A); the presence of a G/C or C/C genotype at Ϫ137 and either a C/C or C/A genotype at Ϫ607 was found to be positively associated with type 1 diabetes, whereas the presence of the A/A genotype at Ϫ607 with either a G/G or G/C genotype at Ϫ137 was not associated with disease. Ide et al. (9) also tested these promoter SNPs in a Japanese type 1 diabetic case-control collection (116 case and 114 control subjects), noting at Ϫ607 (P ϭ 0.023) that the C/A genotype was present in a higher proportion of case compared with control subjects (69% in case and 57.9% in control subjects), whereas the proportion of case subjects with the A/A genotype was decreased (12.1% in case and 26.3% in control subjects). In addition, they found evi-dence (P ϭ 0.006) of an increase in the frequency of the Ϫ607C/-137G haplotype in case subjects (87.9% in case and 73.7% in control subjects) (9) . At Ϫ607, Kretowski et al. (8) also reported an increase in the proportion of the C/A genotype in case relative to control subjects (64.2% case and 56.7% control subjects) and a decrease in the proportion of the A/A genotype in case subjects (0% case and 5.7% control subjects). Thus, despite discrepant results at Ϫ137, data obtained by the two studies at Ϫ607 showed some consistency, a decreased proportion of case subjects carrying the A/A genotype. Kretowski et al. (8) provided no Hardy-Weinberg equilibrium (HWE) information. Testing for deviations from HWE is an important quality control step in population genetic studies (16, 17) , and routine and appropriate testing of genotype data has been strongly advocated by many authors (18 -21) . Deviations from HWE can be very informative. In control subjects, this could indicate that one or more of the model assumptions have been violated or that a genotyping error has occurred. In case subjects, deviation from HWE, assuming sources of error have been eliminated, may indicate the association of a locus with disease.
Consequently, we tested the genotype distributions of Kretowski's control subjects for deviations from HWE and found that both Ϫ607 and Ϫ137 were out of HWE due to an excess of heterozygotes (P ϭ 0.0002 and P ϭ 0.002, respectively). These deviations could be due to control subjects being sampled from different ethnic groups. Kretowski et al. does not provide any ethnicity information and therefore may not have controlled for this. Alternatively, such deviations could indicate a systematic genotyping error; Kretowski makes no mention of the quality control measures used, such as double scoring or duplicate typing. Arguably, heterozygous excess is most likely to occur as a result of genotyping error. Hypernormal control subjects could also cause deviation from HWE, which may indicate that the alternative hypothesis may be true, although the control subjects used by Kretowski et al. were normally selected, so this is unlikely to be the cause of the observed deviation from HWE. Some loci will, by chance, deviate from HWE, and both Ϫ607 and Ϫ137 could be examples of these. However, if these loci were perfectly correct and only deviated from HWE by chance, then it becomes important to use the most appropriate test of association. When deviations from HWE have been observed and they cannot be attributed to genotyping error or to selection or nonrandom mating and are in fact due to some unknown factor, then the Pearson 2 test applied to allele counts is not appropriate, and a test such as the Armitage trend test applied to counts of genotypes should be used (22) (23) (24) (25) in order to reduce the chance of false-positive associations (24) .
Therefore, we sought to assess the validity of these reported associations at Ϫ607 and Ϫ137, including evaluation of the possibility that these SNPs show natural deviation from HWE, in a large sample collection consisting of a U.K. Caucasian case-control collection (1,560 case and 1,715 control subjects typed at Ϫ607 and 4,323 case and 4,610 control subjects typed at Ϫ137) as well as a type 1 diabetic Caucasian collection comprised of families of European ancestry from four countries, including the U.S., the U.K., Norway, and Romania (1,347 families tested at Ϫ137 and 1,356 families tested at Ϫ607). At the Ϫ137 (G3 C) SNP, we had 94% power to detect a susceptibility allele (type 1 error, ␣ ϭ 0.01) with an odds ratio of 1.15 and present at an MAF of 26% in our case-control collection (4,300 case and 4,600 control subjects). We had over 99% power to detect an effect size of 1.3. Similarly, we had 98% power in 1,465 families to detect a susceptibility allele (type 1 error, ␣ ϭ 0.01) conferring a relative risk (RR) of 1.3 and present at an MAF of 0.26 and Ͼ45% power to detect a genetic risk factor present at a comparable MAF and conferring an RR of 1.15. At the Ϫ607 (C3 A) SNP, our power increased, reflecting the increase in allele frequency for this SNP (MAF 0.40), giving 57% power to detect (type 1 error, ␣ ϭ 0.01), in 1,600 case and 1,700 control subjects, a genetic risk factor with an OR of 1.15 and 99.6% power to detect a genetic risk factor with an OR of 1.3.
Genotypes at both loci were in HWE in both our control subjects and unaffected parents (P Ͼ 0. Table 2 ). We assumed a multiplicative model for both Ϫ607 and Ϫ137 in both the case-control collection and the families because this We sought to evaluate, independently of previously reported associations with promoter SNPs, the possibility that common variation elsewhere in IL18 was associated with disease susceptibility. Therefore, we undertook a further study using tag SNPs to test for regional associations across IL18 in our U.K. type 1 diabetic case-control collection (1,561 case and 1,721 control subjects). IL18 has five exons and has been mapped to chromosome 11q22 (27) . Resequencing data from a panel of 23 Caucasian individuals was extracted from the IIPGA "SeattleSNPs" database (as previously described). Thirty-eight SNPs with allele frequencies Ͼ5% were used to select eight tag SNPs with a minimum allelic R 2 of 83.6% for the untyped SNPs. Allele frequencies and predicted R 2 values for the untyped SNPs are tabulated (online appendix Table 2 ). Genotype data were in HWE for the control subjects (P Ͼ 0.05). A multilocus test for an association of the whole gene region was performed (28) , and no evidence for association was found (P ϭ 0.11).
We conclude that common allelic variation in IL18 is unlikely to contribute substantially (OR Ͼ1.15) to type 1 diabetes in the populations tested and recommend routine application of tests for HWE in population-based studies for genetic association.
RESEARCH DESIGN AND METHODS
All families were European Caucasian and comprised of two parents and at least one affected child. The families consist of 528 multiplex families from the Diabetes U.K. Warren 1 collection including 56 simplex families from Yorkshire, 336 multiplex families from the Human Biological Data Interchange (U.S.), 17 multiplex and 246 simplex families from Northern Ireland, 159 Norwegian simplex families, and 261 Romanian simplex families. The 4,323 type 1 diabetic case subjects tested were recruited as part of the GRID (U.K. Genetic Resource Investigating Diabetes) study, a joint project between the University of Cambridge Departments of Pediatrics and Medical Genetics and funded by the Juvenile Diabetes Research Foundation and the Wellcome Trust (29) . The case subjects are Caucasian, and 99.6% are Ͻ16 years of age, with a mean Ϯ SD age at onset of type 1 diabetes of 7.5 Ϯ 4 years (http://wwwgene.cimr.cam.ac.uk/ucdr/grid.shtml). Geographically matched Caucasian control subjects were obtained from the 1958 British Birth Cohort, a longitudinal study involving British citizens born in a particular week in 1958 (http://www.cls.ioe.ac.uk/Cohort/Ncds/mainncds.htm). Attempted and successful genotype counts for all SNPs are tabulated and may be found in online appendix Tables 4 and 5 . Ethical approval by the relevant research ethics committees was obtained for all DNA samples collected, and written informed consent was obtained from the participants. Genotyping. Four SNPs (rs1946518 [IL18 Ϫ607], rs5744232, rs5744237, and rs5744241) were genotyped with Invader (Third Wave Technologies, Madison, WI). PCR optimization and subsequent DNA amplification were conducted for each SNP with primers and for product sizes listed in Table 3 of the online appendix. Four SNPs (rs187238 [IL18 Ϫ137], rs360719, rs2043055, and rs5744281) were genotyped by TaqMan 5Ј nuclease assays (Applied Biosystems, Warrington, U.K.). Design of the TaqMan probes and primers was outsourced to the supplier (Applied Biosystems). All genotyping data obtained was double scored to minimize error. A duplicate plate was typed to check genotyping quality; no mismatches were observed. Statistical analyses. All statistical analyses were performed within STATA8 (http://www.stata.com), making specific use of the Genassoc package (http:// www-gene.cimr.cam.ac.uk/clayton/software/). Genotype data for control subjects and unaffected parents were in HWE (P Ͼ 0.05); a modified test that made allowance for differences in allele frequencies between populations was used (D. Clayton, unpublished work). In the families, the transmission/disequilibrium test was used to test for allelic association under a multiplicative model. Genotype RRs were calculated by conditional logistic regression utilizing case and matched pseudocontrol subjects constructed from the untransmitted parental genotypes (30) . In the case-control collection, tests for association and calculation of ORs were performed using logistic regression. To minimize geographical confounding, case-control analyses were adjusted for 12 geographical subregions of the U.K. (31,32) . For both datasets, a likelihood ratio test was used to test for a difference between the multiplicative model and the Data are n (%) unless otherwise indicated. P values are for overall test of association and not for specific genotypes. There was no evidence of deviation from a multiplicative model (P Ͼ 0.05).
full genotype model, which assumes no specific mode of inheritance. There was no evidence of deviation from a multiplicative model (P Ͼ 0.05). Conditional logistic regression was used to analyze haplotypes in matched sets of affected offspring and pseudocontrol subjects generated from the family data (30) . Haplotypes were reconstructed separately in case and control subjects by imputing phase from the a posteriori distribution using an EM algorithm within the SNPHAP program (http://www-gene.cimr.cam.ac.uk/ clayton/software/). A weighted logistic regression was used to compare haplotypic frequencies in case and control subjects. SNP and flanking sequence data for 23 Caucasian individuals were extracted from the IIPGA database (http://www.innateimmunity.net) and used for tag SNP selection.
